TAA repeat variation in the GRIK2 gene does not influence age at onset in Huntington's disease

Ji Hyun Lee, Jong Min Lee, Eliana Marisa Ramos, Tammy Gillis, Jayalakshmi S. Mysore, Shotaro Kishikawa, Tiffany Hadzi, Audrey E. Hendricks, Michael R. Hayden, Patrick J. Morrison, Martha Nance, Christopher A. Ross, Russell L. Margolis, Ferdinando Squitieri, Cinzia Gellera, Estrella Gomez-Tortosa, Carmen Ayuso, Oksana Suchowersky, Ronald J. Trent, Elizabeth McCuskerAndrea Novelletto, Marina Frontali, Randi Jones, Tetsuo Ashizawa, Samuel Frank, Marie Helene Saint-Hilaire, Steven M. Hersch, Herminia D. Rosas, Diane Lucente, Madaline B. Harrison, Andrea Zanko, Ruth K. Abramson, Karen Marder, Jorge Sequeiros, G. Bernhard Landwehrmeyer, Ira Shoulson, Richard H. Myers, Marcy E. MacDonald, James F. Gusella

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Huntington's disease is a neurodegenerative disorder caused by an expanded CAG trinucleotide repeat whose length is the major determinant of age at onset but remaining variation appears to be due in part to the effect of genetic modifiers. GRIK2, which encodes GluR6, a mediator of excitatory neurotransmission in the brain, has been suggested in several studies to be a modifier gene based upon a 3' untranslated region TAA trinucleotide repeat polymorphism. Prior to investing in detailed studies of the functional impact of this polymorphism, we sought to confirm its effect on age at onset in a much larger dataset than in previous investigations. We genotyped the HD CAG repeat and the GRIK2 TAA repeat in DNA samples from 2,911 Huntington's disease subjects with known age at onset, and tested for a potential modifier effect of GRIK2 using a variety of statistical approaches. Unlike previous reports, we detected no evidence of an influence of the GRIK2 TAA repeat polymorphism on age at motor onset. Similarly, the GRIK2 polymorphism did not show significant modifier effect on psychiatric and cognitive age at onset in HD. Comprehensive analytical methods applied to a much larger sample than in previous studies do not support a role for GRIK2 as a genetic modifier of age at onset of clinical symptoms in Huntington's disease.

Original languageEnglish
Pages (from-to)404-408
Number of pages5
JournalBiochemical and Biophysical Research Communications
Volume424
Issue number3
DOIs
Publication statusPublished - Aug 3 2012

Fingerprint

Huntington Disease
Polymorphism
Age of Onset
Genes
Trinucleotide Repeats
3' Untranslated Regions
Trinucleotide Repeat Expansion
Modifier Genes
Brain
Synaptic Transmission
Neurodegenerative Diseases
Psychiatry
DNA

Keywords

  • Age at onset
  • Genetic modifier
  • GRIK2
  • Huntington's disease (HD)

ASJC Scopus subject areas

  • Biochemistry
  • Biophysics
  • Cell Biology
  • Molecular Biology

Cite this

Lee, J. H., Lee, J. M., Ramos, E. M., Gillis, T., Mysore, J. S., Kishikawa, S., ... Gusella, J. F. (2012). TAA repeat variation in the GRIK2 gene does not influence age at onset in Huntington's disease. Biochemical and Biophysical Research Communications, 424(3), 404-408. https://doi.org/10.1016/j.bbrc.2012.06.120

TAA repeat variation in the GRIK2 gene does not influence age at onset in Huntington's disease. / Lee, Ji Hyun; Lee, Jong Min; Ramos, Eliana Marisa; Gillis, Tammy; Mysore, Jayalakshmi S.; Kishikawa, Shotaro; Hadzi, Tiffany; Hendricks, Audrey E.; Hayden, Michael R.; Morrison, Patrick J.; Nance, Martha; Ross, Christopher A.; Margolis, Russell L.; Squitieri, Ferdinando; Gellera, Cinzia; Gomez-Tortosa, Estrella; Ayuso, Carmen; Suchowersky, Oksana; Trent, Ronald J.; McCusker, Elizabeth; Novelletto, Andrea; Frontali, Marina; Jones, Randi; Ashizawa, Tetsuo; Frank, Samuel; Saint-Hilaire, Marie Helene; Hersch, Steven M.; Rosas, Herminia D.; Lucente, Diane; Harrison, Madaline B.; Zanko, Andrea; Abramson, Ruth K.; Marder, Karen; Sequeiros, Jorge; Bernhard Landwehrmeyer, G.; Shoulson, Ira; Myers, Richard H.; MacDonald, Marcy E.; Gusella, James F.

In: Biochemical and Biophysical Research Communications, Vol. 424, No. 3, 03.08.2012, p. 404-408.

Research output: Contribution to journalArticle

Lee, JH, Lee, JM, Ramos, EM, Gillis, T, Mysore, JS, Kishikawa, S, Hadzi, T, Hendricks, AE, Hayden, MR, Morrison, PJ, Nance, M, Ross, CA, Margolis, RL, Squitieri, F, Gellera, C, Gomez-Tortosa, E, Ayuso, C, Suchowersky, O, Trent, RJ, McCusker, E, Novelletto, A, Frontali, M, Jones, R, Ashizawa, T, Frank, S, Saint-Hilaire, MH, Hersch, SM, Rosas, HD, Lucente, D, Harrison, MB, Zanko, A, Abramson, RK, Marder, K, Sequeiros, J, Bernhard Landwehrmeyer, G, Shoulson, I, Myers, RH, MacDonald, ME & Gusella, JF 2012, 'TAA repeat variation in the GRIK2 gene does not influence age at onset in Huntington's disease', Biochemical and Biophysical Research Communications, vol. 424, no. 3, pp. 404-408. https://doi.org/10.1016/j.bbrc.2012.06.120
Lee, Ji Hyun ; Lee, Jong Min ; Ramos, Eliana Marisa ; Gillis, Tammy ; Mysore, Jayalakshmi S. ; Kishikawa, Shotaro ; Hadzi, Tiffany ; Hendricks, Audrey E. ; Hayden, Michael R. ; Morrison, Patrick J. ; Nance, Martha ; Ross, Christopher A. ; Margolis, Russell L. ; Squitieri, Ferdinando ; Gellera, Cinzia ; Gomez-Tortosa, Estrella ; Ayuso, Carmen ; Suchowersky, Oksana ; Trent, Ronald J. ; McCusker, Elizabeth ; Novelletto, Andrea ; Frontali, Marina ; Jones, Randi ; Ashizawa, Tetsuo ; Frank, Samuel ; Saint-Hilaire, Marie Helene ; Hersch, Steven M. ; Rosas, Herminia D. ; Lucente, Diane ; Harrison, Madaline B. ; Zanko, Andrea ; Abramson, Ruth K. ; Marder, Karen ; Sequeiros, Jorge ; Bernhard Landwehrmeyer, G. ; Shoulson, Ira ; Myers, Richard H. ; MacDonald, Marcy E. ; Gusella, James F. / TAA repeat variation in the GRIK2 gene does not influence age at onset in Huntington's disease. In: Biochemical and Biophysical Research Communications. 2012 ; Vol. 424, No. 3. pp. 404-408.
@article{2b02a474d4604297bc33c2aebcdb7907,
title = "TAA repeat variation in the GRIK2 gene does not influence age at onset in Huntington's disease",
abstract = "Huntington's disease is a neurodegenerative disorder caused by an expanded CAG trinucleotide repeat whose length is the major determinant of age at onset but remaining variation appears to be due in part to the effect of genetic modifiers. GRIK2, which encodes GluR6, a mediator of excitatory neurotransmission in the brain, has been suggested in several studies to be a modifier gene based upon a 3' untranslated region TAA trinucleotide repeat polymorphism. Prior to investing in detailed studies of the functional impact of this polymorphism, we sought to confirm its effect on age at onset in a much larger dataset than in previous investigations. We genotyped the HD CAG repeat and the GRIK2 TAA repeat in DNA samples from 2,911 Huntington's disease subjects with known age at onset, and tested for a potential modifier effect of GRIK2 using a variety of statistical approaches. Unlike previous reports, we detected no evidence of an influence of the GRIK2 TAA repeat polymorphism on age at motor onset. Similarly, the GRIK2 polymorphism did not show significant modifier effect on psychiatric and cognitive age at onset in HD. Comprehensive analytical methods applied to a much larger sample than in previous studies do not support a role for GRIK2 as a genetic modifier of age at onset of clinical symptoms in Huntington's disease.",
keywords = "Age at onset, Genetic modifier, GRIK2, Huntington's disease (HD)",
author = "Lee, {Ji Hyun} and Lee, {Jong Min} and Ramos, {Eliana Marisa} and Tammy Gillis and Mysore, {Jayalakshmi S.} and Shotaro Kishikawa and Tiffany Hadzi and Hendricks, {Audrey E.} and Hayden, {Michael R.} and Morrison, {Patrick J.} and Martha Nance and Ross, {Christopher A.} and Margolis, {Russell L.} and Ferdinando Squitieri and Cinzia Gellera and Estrella Gomez-Tortosa and Carmen Ayuso and Oksana Suchowersky and Trent, {Ronald J.} and Elizabeth McCusker and Andrea Novelletto and Marina Frontali and Randi Jones and Tetsuo Ashizawa and Samuel Frank and Saint-Hilaire, {Marie Helene} and Hersch, {Steven M.} and Rosas, {Herminia D.} and Diane Lucente and Harrison, {Madaline B.} and Andrea Zanko and Abramson, {Ruth K.} and Karen Marder and Jorge Sequeiros and {Bernhard Landwehrmeyer}, G. and Ira Shoulson and Myers, {Richard H.} and MacDonald, {Marcy E.} and Gusella, {James F.}",
year = "2012",
month = "8",
day = "3",
doi = "10.1016/j.bbrc.2012.06.120",
language = "English",
volume = "424",
pages = "404--408",
journal = "Biochemical and Biophysical Research Communications",
issn = "0006-291X",
publisher = "Academic Press Inc.",
number = "3",

}

TY - JOUR

T1 - TAA repeat variation in the GRIK2 gene does not influence age at onset in Huntington's disease

AU - Lee, Ji Hyun

AU - Lee, Jong Min

AU - Ramos, Eliana Marisa

AU - Gillis, Tammy

AU - Mysore, Jayalakshmi S.

AU - Kishikawa, Shotaro

AU - Hadzi, Tiffany

AU - Hendricks, Audrey E.

AU - Hayden, Michael R.

AU - Morrison, Patrick J.

AU - Nance, Martha

AU - Ross, Christopher A.

AU - Margolis, Russell L.

AU - Squitieri, Ferdinando

AU - Gellera, Cinzia

AU - Gomez-Tortosa, Estrella

AU - Ayuso, Carmen

AU - Suchowersky, Oksana

AU - Trent, Ronald J.

AU - McCusker, Elizabeth

AU - Novelletto, Andrea

AU - Frontali, Marina

AU - Jones, Randi

AU - Ashizawa, Tetsuo

AU - Frank, Samuel

AU - Saint-Hilaire, Marie Helene

AU - Hersch, Steven M.

AU - Rosas, Herminia D.

AU - Lucente, Diane

AU - Harrison, Madaline B.

AU - Zanko, Andrea

AU - Abramson, Ruth K.

AU - Marder, Karen

AU - Sequeiros, Jorge

AU - Bernhard Landwehrmeyer, G.

AU - Shoulson, Ira

AU - Myers, Richard H.

AU - MacDonald, Marcy E.

AU - Gusella, James F.

PY - 2012/8/3

Y1 - 2012/8/3

N2 - Huntington's disease is a neurodegenerative disorder caused by an expanded CAG trinucleotide repeat whose length is the major determinant of age at onset but remaining variation appears to be due in part to the effect of genetic modifiers. GRIK2, which encodes GluR6, a mediator of excitatory neurotransmission in the brain, has been suggested in several studies to be a modifier gene based upon a 3' untranslated region TAA trinucleotide repeat polymorphism. Prior to investing in detailed studies of the functional impact of this polymorphism, we sought to confirm its effect on age at onset in a much larger dataset than in previous investigations. We genotyped the HD CAG repeat and the GRIK2 TAA repeat in DNA samples from 2,911 Huntington's disease subjects with known age at onset, and tested for a potential modifier effect of GRIK2 using a variety of statistical approaches. Unlike previous reports, we detected no evidence of an influence of the GRIK2 TAA repeat polymorphism on age at motor onset. Similarly, the GRIK2 polymorphism did not show significant modifier effect on psychiatric and cognitive age at onset in HD. Comprehensive analytical methods applied to a much larger sample than in previous studies do not support a role for GRIK2 as a genetic modifier of age at onset of clinical symptoms in Huntington's disease.

AB - Huntington's disease is a neurodegenerative disorder caused by an expanded CAG trinucleotide repeat whose length is the major determinant of age at onset but remaining variation appears to be due in part to the effect of genetic modifiers. GRIK2, which encodes GluR6, a mediator of excitatory neurotransmission in the brain, has been suggested in several studies to be a modifier gene based upon a 3' untranslated region TAA trinucleotide repeat polymorphism. Prior to investing in detailed studies of the functional impact of this polymorphism, we sought to confirm its effect on age at onset in a much larger dataset than in previous investigations. We genotyped the HD CAG repeat and the GRIK2 TAA repeat in DNA samples from 2,911 Huntington's disease subjects with known age at onset, and tested for a potential modifier effect of GRIK2 using a variety of statistical approaches. Unlike previous reports, we detected no evidence of an influence of the GRIK2 TAA repeat polymorphism on age at motor onset. Similarly, the GRIK2 polymorphism did not show significant modifier effect on psychiatric and cognitive age at onset in HD. Comprehensive analytical methods applied to a much larger sample than in previous studies do not support a role for GRIK2 as a genetic modifier of age at onset of clinical symptoms in Huntington's disease.

KW - Age at onset

KW - Genetic modifier

KW - GRIK2

KW - Huntington's disease (HD)

UR - http://www.scopus.com/inward/record.url?scp=84864757021&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864757021&partnerID=8YFLogxK

U2 - 10.1016/j.bbrc.2012.06.120

DO - 10.1016/j.bbrc.2012.06.120

M3 - Article

C2 - 22771793

AN - SCOPUS:84864757021

VL - 424

SP - 404

EP - 408

JO - Biochemical and Biophysical Research Communications

JF - Biochemical and Biophysical Research Communications

SN - 0006-291X

IS - 3

ER -